Lexeo Therapeutics LXEO 深 沪
等待开盘 12-19 09:30:00 美东时间
9.96
+0.850
+9.33%
华盛通- 最 高10.10
- 今 开9.68
- 成交量 239.30万股
- 最 低 9.43
- 昨 收 9.11
- 总市值 7.27亿
- 52周最高 10.56
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.45
- 委 比 -38.93%
- 总股本 7298.73万
- 历史最高 22.33
- 量 比 2.48
- 振 幅 7.35%
- 历史最低 1.45
- 每 手 1
- 风险率 2.25%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅101%！12家机构集体上调美光目标价；Insmed、RPM、Vital Farms等遭多家大行下调评级
今日重点评级关注：Ascendiant Capital：维持Society Pass"买入"评级，目标价从22美元升至22.5美元；HC Wainwright & Co.：维持Climb Bio"买入"评级，目标价从9美元升至11美元
今天 10:15
Lexeo Therapeutics shares are trading higher after Raymond James initiated coverage on the stock with a Strong Buy rating and announced a $25 price target.
Lexeo Therapeutics shares are trading higher after Raymond James initiated cove...
12-18 22:13
美股大行评级 | 绩后分化！甲骨文遭14家大行集体下调目标价；新思科技、Planet获多家机构上调目标价！
今日重点评级关注：HC Wainwright & Co.：维持Moleculin Biotech"买入"评级，目标价从4美元升至22美元；HC Wainwright & Co.：上调Soluna Holdings评级至"买入"，目标价5美元
12-12 10:24
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $17 price target.
12-11 20:19
Lexeo Therapeutics to Host Virtual Key Opinion Leader Event at the 22nd Global Cardiovascular Clinical Trialists (CVCT) Forum
Lexeo Therapeutics will host a virtual event on December 9 at 3 PM ET during the 22nd Global Cardiovascular Clinical Trialists Forum. The session, titled "A Clinician’s Perspective: Holistic Approach to Managing PKP2-Associated Arrhythmogenic Cardiomyopathy," will feature Dr. Victoria Parikh, an expert in this condition. Investors and analysts can register via Lexeo’s website, with a replay available post-event. Lexeo is a clinical-stage genetic ...
12-04 13:00
美股大行评级 | 最高352美元！14家机构连夜上调英伟达目标价；劳氏、塔吉特、Wix.com等遭多家机构下调目标价
今日重点评级关注：Ascendiant Capital：维持Aclarion"买入"评级，目标价从22美元升至23美元；HC Wainwright & Co.：维持Cullinan Therapeutics"买入"评级，目标价从24美元升至26美元
11-21 15:50
Cantor Fitzgerald Initiates Coverage On Lexeo Therapeutics with Overweight Rating, Announces Price Target of $19
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight rating and announces Price Target of $19.
11-20 19:58
美股大行评级 | 绩后评级扎堆！高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；DoorDash、多邻国、Figma、飞塔信息、HubSpot等遭下调目标价
高通、ARM、礼来、Snap、Robinhood等获多家大行上调目标价；Adient、DoorDash、多邻国、Figma、飞塔信息、HubSpot、康丽数码等遭大行下调目标价
11-07 10:14
Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $17 Price Target
Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $17 price target.
11-06 08:18
Lexeo Therapeutics Q3 EPS $(0.33) Beats $(0.54) Estimate
Lexeo Therapeutics (NASDAQ:LXEO) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.54) by 38.78 percent. This is a 62.92 percent increase over losses of $(0.89) per share
11-05 20:37
